Review of liraglutide versus sitagliptin for patients with uncontrolled type 2 diabetes: more effective HbA 1c reduction with subcutaneous GLP-1 receptor agonist versus an oral DPP-4 inhibitor.
Nadeau
Daniel A
DA
HealthReach Diabetes Endocrine Nutrition Center, 881 Lafayette Rd., Hampton, NH 03842, USA. dnadeaumd@gmail.com